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was 49 years (range, 21–71 years). Ten patients underwent a sibling
transplantation (5 standard regimen, 5 reduced intensity), and 11
underwent an unrelated transplantation (5 standard regimen, 6
reduced intensity); graft T-cell depletion was done in 15 patients
(Campath-1H in 7, OKT3 in 8). Neutropenia was observed in 5
patients, resolving in all of them. VGC was discontinued tempo-
rarily in these 5 patients until they recovered from neutropenia.
Four of them received concomitant mycophenolate mofetil. No
adverse effects were otherwise reported. The median follow-up
after transplantation is 12 months. Six patients died during the
study, from disease progression (2 patients), fungal infection (1
patient), or GVHD (3 patients). None of the 21 patients experi-
enced CMV reactivation or disease while on VGC. Conclusions:
These early results suggest that VGC has a role in the posttrans-
plantation setting, and that further evaluation of VGC in CMV
prophylaxis or preemptive therapy is needed.
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ACTUALIZING A WELLNESS PROGRAM AND WELLNESS ROOM IN THE
ONCOLOGY SETTING: GETTING A PROGRAM THROUGH A LARGE IN-
STITUTION
Galgay, L., Swift, S., Cusack, G., Jones-Wells, A., Rivera, P.,
Chisholm, L. The National Institutes of Health, Bethesda, MD.
The Clinical Center (CC) of the National Institutes of Health
(NIH) is a hospital solely dedicated to conducting biomedical
research. Participation in the rigors of a phase I or II clinical trial
requires inner strength, support, and ability to follow through with
the demands of research. Nurses on the Oncology, Experimental
Transplantation Unit at the CC acknowledge the special needs of
their patients, caregivers, and staff, and strive to ﬁnd ways to lessen
the impact of these demands. A group of oncology nurses at the
CC formed a Complementary and Alternative Medicine (CAM)
Cancer Nursing Interest Group. A review of the literature reveals
that a focus on patients’ psychological, social, physical, and spiri-
tual needs promotes improved quality of life in oncology patients.
The CAM Interest Group recognized the importance of integra-
tive therapies as one strategy to assist patients in dealing with their
chronic illness. This presentation outlines the development and
inception of a wellness program to aid patients in dealing with
chronic illness using integrative therapies such as relaxation ther-
apy, guided imagery, and a “room for silence.”
The “plan-do-check-act” model serves as our conceptual model
for development and evaluation of the program. Benchmarking
with preeminent institutions nationwide, and identiﬁcation of key
stakeholders within the institution, as well as the National Cancer
Institute (NCI) and the National Center for Complementary and
Alternative Medicine (NCCAM), was instrumental in the develop-
ment of the program.
With visionary nursing leadership and extensive collaboration
with the CC interdisciplinary team, the program has been incor-
porated and follows the credentialing guidelines proposed by the
CC’s Integrative Medicine Taskforce. Self-care, empowerment,
healing versus curing, relaxation, and comfort are emphasized, and
an examination of theories and models is used for health education
and promotion. Dedicated space has been allocated for a “room for
silence,” which is designed for meditation, prayer, imagery, and
journaling. Patients and staff evaluate the wellness program on an
ongoing basis and changes are incorporated based on feedback.
Incorporating a wellness program fosters improved patient out-
comes, enhances quality of life for oncology patients, and serves as
a model for integrative care.
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URSODIOL-BASED PROPHYLAXIS FOR VENO-OCCLUSIVE DISEASE
(VOD): A RETROSPECTIVE RISK-BASED REVIEW OF OUTCOMES FOL-
LOWING ALLOGENEIC STEM CELL TRANSPLANTATION
Thompson, J.M., Akard, L.P., Dugan, M.J., English, K., Jansen, J.
Indiana Blood & Marrow Transplantation, Indianapolis, IN.
A total of 307 sequential patients allografted at our institution
over the past decade were evaluated retrospectively to study treat-
ment-related hepatotoxicity, and prevention thereof, following the
use of various ursodiol-based VOD prophylaxis regimens. The
patient group comprised 178 males and 129 females, median age 42
years. There were 227 related and 80 unrelated donors, 271
matched and 36 mismatched. Diagnoses included acute leukemia
in 129 patients (42%), chronic leukemia in 89 patients (29%),
lymphoma in 37 patients (12%), myelodysplasia in 21 patients
(7%), myeloma in 15 patients (5%), aplastic anemia in 10 patients
(3%), and other in 6 patients (2%). A total of 158 patients (51%)
received TBI, 112 patients (36%) received busulfan, and 37 pa-
tients (12%) received methotrexate. All patients whose bilirubin
exceeded 2.0 mg/dL postgrafting (166 patients; 54%) were evalu-
ated for cause. The mean day (D) of maximal bilirubin elevation for
this group was D19. Non-VOD causes included regimen-related
toxicity in 57 patients (34%), GVHD in 50 patients (30%), infec-
tion/sepsis/multiorgan dysfunction in 19 patients (12%), and
ABO-realted hemolysis in 18 patients (11%). The diagnosis of
VOD was made by criteria described previously. VOD accounted
for the cause of hyperbilirubinemia in 23 patients in this subset of
166 patients (14%). Of the total group of 307 patients, 164 patients
(53%) received VOD prophylaxis, 38 patients (23%) received oral
ursodiol (Urso) alone (600–900 mg/day), 69 patients (42%) re-
ceived IV Urso  heparin (Hep)(800 U/hr), 54 patients (33%)
received SQ Urso  Lovenox (Lov)(40 mg/day), and 3 patients
(2%) received Hep alone. Overall, 23 patients (7.5%) developed
VOD, with only 7 patients dying due to VOD (2.3%). The inci-
dence of VOD was not signiﬁcantly different for / Urso (7.5%
vs 7.6%), / Lov (7.4% vs 7.5%), / Hep (11.1% vs 6.4%;
P  .18); / Urso  Lov (7.4% vs 7.5%), and / Urso Hep
(7.2% vs 7.6%). Data were also analyzed for the effect of 7 known
risk factors for VOD: age  40 years, unrelated donor, preparative
regimen including busulfan or TBI, baseline AST, methotrexate
for GVHD prophylaxis, and history of liver disease. Risk factors (f)
for VOD occurred as follows: 0(f), 5 (2%); 1(f), 90 (29%); 2(f), 150
(49%); 3(f), 54 (17%); 4(f), 8 (3%). The occurrence of VOD (%)
correlated with the number of risk factors (f) pregrafting: 0(f), 0/5
(0%); 1(f), 5/90 (6%); 2(f), 10/150 (7%); 3(f), 7/54 (13%); 4(f), 1/8
(12%). The overall incidence of VOD, and related death, is lower
in this series than historical reports. The beneﬁt of ursodiol-based
prophylactic regimens appears to be greatest in patients with 2 or
fewer VOD-related risk factors.
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VORICONAZOLE (VOR) IS SAFE AND EFFECTIVE AS PROPHYLACTIC ANTI-
FUNGAL THERAPY FOR ALLOGENEIC STEM CELL TRANSPLANTATION (AT)
Martin, T.1, O’Malley, R.2, Working, M.2, Guglielmo, J.1,
Fischbach, N.1, Damon, L.1, Navarro, W.1, Kaplan, L.1, Linker, C.1
1University of California, San Francisco, San Francisco, CA; 2Wake
Forest Medical School, Winston Salem, NC.
Background: Despite ﬂuconazole (FLU) prophylaxis in AT,
invasive fungal infection (IFI) continues to cause signiﬁcant mor-
bidity and mortality. VOR is a second-generation triazole with
broad-spectrum activity. Since August 2002, VOR has been used as
antifungal prophylaxis at UCSF Medical Center. The goals of this
study were to evaluate the incidence of IFI up to d100 and assess
safety and organ toxicity (OT). Methods: The records of patients
receiving VOR prophylaxis from August 2002 to May 2004 were
reviewed. Demographics, conditioning, stem cell source, HLA
status, laboratory and radiology results, OT, and survival were
analyzed. All patients were hospitalized throughout AT. Tacroli-
mus and MTX / MMF were used for GVHD prophylaxis.
VOR (4 mg/kg twice a day IV/PO) was administered through day
100 post-AT. EORTC criteria were used to assess for IFI.
Results: A total of 72 patients were identiﬁed (44 males and 28
females, mean age 54 years [range, 19–70]). Of these, 41 patients
received low-intensity conditioning and 31 received myeloablative
therapy. PBSCs were used more frequently than BM (60 vs 12).
Sibling donors were used for 37 patients; unrelated donors, for 35
patients. The 100- and 180-day TRM rates were 8% and 13%.
The incidence of grade II-IV aGVHD was 16%. Two patients
(3%) developed deﬁnitive IFI (1 mucor and 1 aspergillus plus
scedosporium). No probable IFIs were identiﬁed. Both patients
with deﬁnitive IFI died, 1 from grade IV GVHD and 1 from
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multiorgan failure. No unexpected OT was noted. Fifty-four of the
72 patients (75%) received VOR until day 100 without interrup-
tion. The reasons for VOR discontinuation were increased LFTs
in 11 patients, prolonged QTc in 2, and suspected resistant IFI in
2. The LFT increases were transient. The median total bilirubin,
alkaline phosphatase, and AST values were 1.3 mg/dL, 134 U/L,
and 34 U/L, respectively. Eight patients developed total biliru-
bin  6 mg/dL, and 3 had VOD. Four patients restarted VOR
following improved LFTs. No signiﬁcant cardiac toxicity was
noted, despite a QTc of  500 msec in 10 patients. The mean
increase in QTc after starting VOR was 34 msec (n  36). The
mean peak creatinine level was 1.5 mg/dL. Four patients required
HD. Engraftment did not appear to be adversely affected, with
means of 14 days to ANC  0.5/L and of 20 days to platelets 
50 103/L. VOR did uniformly increase serum tacrolimus levels,
necessitating a 60% reduction in tacrolimus dosing. Conclusions:
VOR appears safe and effective as prophylaxis for AT. Tacrolimus
levels must be closely monitored. A randomized trial comparing
VOR to FLU in AT is warranted.
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ANTIFUNGAL PROPHYLAXIS WITH VORICONAZOLE IN ALLOGENEIC
HEMATOPOIETIC STEM CELL TRANSPLANTATION RECIPIENTS
Magalhaes-Silverman, M., Carter, T., Hohl, R., Shamsuddin, H.,
Gingrich, R. University of Iowa, Iowa City, IA.
Background: Invasive fungal infection (IFI) remains a major
cause of morbidity and mortality in recipients of allogeneic hema-
topoietic stem cell transplantation (HSCT). In many transplanta-
tion centers, Aspergillus has been the leading cause of death from
fungal infections. Voriconazole is a triazole with broad-spectrum
antifungal activity against several molds, including Aspergillus. In
our institution, voriconazole was instituted as antifungal prophy-
laxis in July 2002. Before the institution of voriconazole, invasive
aspergillosis (IA) was the most commom fungal infection in our
allogeneic HSCT population, with 3 years of surveillance revealing
a cumulative incidence of proven or probable IA of 12%. Meth-
ods: From July 2002 to March 2004, 40 adult patients undergoing
allogeneic HSCT received oral voriconazole 200 mg every 12
hours from initiation of the preparative regimen until at least
posttransplantation day 100. After day 100, voriconazole was
continued in patients requiring corticosteroids for therapy of
GVHD. Intravenous voriconazole was allowed in patients not able
to take oral medications. All these patients were at high risk for
Aspergillus infection. Diagnoses included myeloid malignancies in
23 patients, lymphoid malignancies in 16, and renal cell cancer in
1. Median patient age was 47 years. Some 75% of the patients had
advanced disease, and 50% received an unrelated donor transplant.
T-cell depletion was achieved using either OKT3 or Campath-1H
in 75% of the patients. GVHD requiring high-dose corticosteroids
occurred in 50% of the patients. Results: Voriconazole had to be
discontinued in 1 patient due to hallucinations; this patient devel-
oped and died from IA. Three cases of candidemia caused by
Candida glabrata were diagnosed (all 3 cases caused by voricon-
azole-resistant organisms). Disseminated zygomycosis was identi-
ﬁed and caused the death of 2 patients at days 25 and 196 after
transplantation. Conclusions: In this high-risk patient population,
only 1 case of IA was diagnosed. This compares favorably with
historical results: However, 2 cases of disseminated zygomycosis
were diagnosed. Our experience raises concern regarding the
changing epidemiology of IFI as practices using prophylactic an-
tifungal agents evolve.
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PHARMACOKINETICS OF HIGH-DOSE WEEKLY AMBISOME (LIPOSO-
MAL AMPHOTERICIN B) ANTIFUNGAL PROPHYLAXIS IN PEDIATRIC
BONE MARROW TRANSPLANTATION (BMT) PATIENTS
Mehta, P.A., Vinks, A.A., Filipovich, A.H., Vaughn, G.A.,
Fearing, D.N., Sper, C., Davies, S.M. Cincinnati Children’s Hospital
Medical Center, Cincinnati, OH.
Background: Disseminated fungal infection is a major cause of
morbidity and mortality in children undergoing BMT. Prophylac-
tic oral triazoles are limited by poor absorption, interindividual
variation in metabolism, and hepatic toxicity. Ambisome is shown
to produce higher plasma and tissue concentrations and has a
better safety proﬁle than the parent drug amphotericin B; however,
it requires frequent intravenous administration. Both animal (mu-
rine models for Candida/Histoplasma) and human (adult) data show
measurable plasma and tissue levels at 7 days after a single dose
(2–20 mg/kg) of Ambisome. We hypothesized that weekly high-
dose Ambisome will provide adequate fungal prophylaxis for im-
munocompromised children. This dosing schedule will improve
compliance and broaden the applicability of Ambisome to a larger
patient population.Methods: A total of 14 children (M/F ratio 2:1,
age 10 years [mean age, 3.3 years]) with various hematologic
conditions, metabolic disorders, and immunodeﬁciency syndromes
at risk for invasive fungal infection received once-a-week intrave-
nous Ambisome prophylaxis at the dose of 10 mg/kg given over 2
hours. Blood samples were drawn for phrmacokinetic (PK) mea-
surements around the ﬁrst and the fourth weekly doses. PK analysis
of single-dose and steady-state data was conducted using standard
noncompartmental methods. Individual plasma trough concentra-
tions were determined by visual inspection of the plasma concen-
tration time proﬁles. The area under the plasma concentration
versus time curve (AUC0-) was determined using the log-linear
trapezoidal rule. Total body clearance (CL), volume of distribution
(Vz), and terminal half-life (T1⁄2) were calculated using standard
equations. Results: Ambisome was well tolerated at this dosage.
Half-life measured in this pediatric population appears to be
shorter than reported in adults (45 hours vs 152 hours). Volume of
distribution and clearance were higher compared to adult reports
and correlated positively with body weight (r2  0.62 for Vz; r2 
0.28 for Cl). Plasma levels at 7 days (Cmin) were not signiﬁcantly
different after the ﬁrst and fourth doses, suggesting no accumula-
tion over the course of therapy. Conclusions: Our data show
measurable plasma levels present 7 days after the dose. Adult
studies show tissue concentrations  10-fold higher than plasma
concentrations, suggesting that once-weekly dosing, as described
in this study, likely provides useful protection against fungal infec-
tion.
Table 1. Pharmacokinetic Parameters After Weekly Ambisome (10
mg/kg)
Parameters (Unit)
After Single
Dose (n  12)
After Multiple
Doses (n  9)
T1⁄2 (h) 45.44 (15.43) 58.94 (26.42)
Day 7 plasma trough
(Cmin; mg/L) 0.23 (0.14) 0.51 (0.46)
AUC0-INF (hr  mg/L) 157.51 (71.71) 230.08 (132.67)
Vz (L/kg) 4.29 (1.01) 4.97 (2.96)
Cl (L/hr/kg) 0.0742 (0.0341) 0.0669 (0.0442)
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EVALUATION OF ANTIBIOTIC CYCLING AND PROPHYLAXIS FOR NEU-
TROPENIC FEVER WITHIN A BLOOD AND MARROW TRANSPLANTA-
TION UNIT
Craig, M.1, Cumpston, A.1, Shields, R.2, Devetten, M.3, Sarwari, A.1,
Ericson, S.1 1West Virginia University, Morgantown, WV; 2St. Jo-
seph’s/ Candler Health System, Savannah, GA; 3University of Ne-
braska, Omaha, NE.
Background: Bacterial resistance to antibiotics is an increasing
problem and associated with signiﬁcant morbidity and mortality.
Patients undergoing HSC transplantation and treatment for he-
matologic malignancy are at high risk of infection. We evaluated
whether rotating the empiric antibiotics for patients who develop
neutropenic fever in this setting resulted in decreased emergence
of resistant organisms and decreased vancomycin use. Methods:
Within the BMTU, all patients with neutropenic fever were em-
pirically treated with piperacillin plus gentamicin (intermittent
dosing) from January 1999 to February 2002. From March 2002
through June 2004, 3 antibiotic regimens were cycled every 8
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